Indivior PLC (NASDAQ:INDV) Short Interest Update

Indivior PLC (NASDAQ:INDV) was the target of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 800,900 shares, a decrease of 15.7% from the September 15th total of 950,000 shares. Based on an average daily volume of 859,800 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.6% of the company’s stock are short sold.

Hedge Funds Weigh In On Indivior

Several institutional investors and hedge funds have recently modified their holdings of INDV. Toronto Dominion Bank boosted its holdings in shares of Indivior by 58.0% during the 1st quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock worth $44,872,000 after buying an additional 769,000 shares during the period. Susquehanna International Group Ltd. acquired a new stake in Indivior during the second quarter worth approximately $3,224,000. Millennium Management LLC boosted its holdings in shares of Indivior by 48.1% during the second quarter. Millennium Management LLC now owns 493,313 shares of the company’s stock worth $7,952,000 after acquiring an additional 160,282 shares during the period. M&G Plc acquired a new position in shares of Indivior in the first quarter valued at approximately $2,518,000. Finally, FourWorld Capital Management LLC bought a new position in shares of Indivior during the first quarter worth approximately $2,215,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Stock Performance

Shares of Indivior stock traded up $0.44 during trading on Monday, hitting $7.90. 4,143,010 shares of the stock were exchanged, compared to its average volume of 424,575. The company has a current ratio of 0.85, a quick ratio of 0.68 and a debt-to-equity ratio of 23.50. The company has a fifty day moving average price of $10.99 and a 200-day moving average price of $14.62. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of 773.00 and a beta of 0.68. Indivior has a 1-year low of $7.33 and a 1-year high of $23.22.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.04. The company had revenue of $299.00 million during the quarter, compared to analysts’ expectations of $285.90 million. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. As a group, equities analysts predict that Indivior will post 1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on INDV shares. Craig Hallum decreased their price objective on Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a report on Friday. Piper Sandler reaffirmed an “overweight” rating and set a $15.00 price target (down previously from $22.00) on shares of Indivior in a research report on Friday.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.